Menu
Search
Home > Courses > Diagnosis and Treatment of Anal Cancer: High Cure Rates, but at What Cost?

Diagnosis and Treatment of Anal Cancer: High Cure Rates, but at What Cost?

Diagnosis and Treatment of Anal Cancer: High Cure Rates, but at What Cost?
Play
Sorry, this learning module is not available for mobile devices.
Original Release Date: 9/10/2018
Termination Date: 09/11/2021
Review Date: 12/6/2018
Presenters
  • Peter S Kozuch, MD
    Associate Professor
    Icahn School of Medicine at Mount Sinai
  • Stephen E. Goldstone, MD, FACS
    Assistant Clinical Professor of Surgery
    Mount Sinai School of Medicine
Learning Objectives / Desired Outcomes
At the completion of this educational activity, participants will:
  1. Know the standard therapy for anal cancer.
  2. Appreciate atypical presentations of anal cancer.
  3. Be aware of the morbidity of anal cancer treatment.
  4. Understand post treatment follow-up.
Presenter Bios
Peter Kozuch, MD
Peter S. Kozuch is an Associate Professor of Hematology-Oncology at the Icahn School of Medicine at Mount Sinai, Associate Program Director Mount Sinai Health System Fellowship in Hematology and Oncology.. As director of gastrointestinal medical oncology and codirector of the Continuum Cancer Centers of New York multidisciplinary gastrointestinal tumor board over the past several years, his practice and research is completely enmeshed with the practice advancements and effort of colleagues in diagnostic radiology, surgical pathology, radiation oncology, colorectal surgery, surgical oncology and hepatobiliary surgery.
Stephen Goldstone, MD, FACS
Stephen E. Goldstone is an Assistant Clinical Professor of Surgery at The Icahn School of Medicine at Mount Sinai and has a surgical practice in New York City. Dr. Goldstone has spoken at conferences around the world and has done extensive research on human papillomavirus (HPV). His work has been published in many prestigious medical journals, and is currently involved in testing both prevention and treatment procedures for HPV. He is a past-president of the International Anal Neoplasia Society and a member of the AIDS Malignancy Consortium.
Continuing Education Credit

This CME activity was approved for AMA PRA Category 1 Credit on September 11, 2018 and will terminate September 10, 2021.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
  • You must achieve at least 70% correct to receive your CME certificate.
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.

 Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement 

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.  

  • Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
  • Dr. Stephen E. Goldstone (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Research support from Medtronic, Antiva, and Inovio; Consultant to Merck, Medtronic, and THD America. Dr. Goldstone submitted his slides in advance for adequate peer review, and will support his presentation and clinical recommendations with the best available evidence from the medical literature.
  • Dr. Peter S. Kozuch (Presenter) has no relevant financial relationships to disclose. Dr. Kozuch submitted his slides in advance for adequate peer review, and will support his presentation and clinical recommendations with the best available evidence from the medical literature. 

Financial Support

This meeting of the Physicians’ Research Network (PRN) and enduring material were funded in part by educational grants from: Gilead Sciences, Janssen Therapeutics (a division of Janssen Products, LP), Merck & Co., and ViiV Healthcare.

Details: 

  • This online video and post-activity evaluation are one hour in length. 
  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
PRN Learning Modules